EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Related news for (EYPT)
- Breaking News: MoBot’s Latest Update as of 05/28/25 12:00 PM
- eyepoint pharmaceuticals announces closing of upsized public offering and full exercise of option to purchase additional shares
- eyepoint pharmaceuticals announces pricing of upsized public offering
- eyepoint pharmaceuticals announces proposed public offering of common stock
- 24/7 Market News Snapshot 28 October, 2024 – EyePoint Pharmaceuticals, Inc. Common Stock (NASDAQ:EYPT)